Natrecor Safety Labeling Change Likely, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is in discussions with FDA to “ensure that correct conclusions are in label.” Adverse publicity from Circulation article questioning kidney safety of CHF drug is having an impact; mortality analysis in JAMA will raise more questions.